Pharma: Page

  • A white sign bears the word Sanofi at a road entrance to an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Sanofi, Teva say study results show gut disease drug could be ‘best in class’

    Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.

    By • Dec. 17, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novo builds up manufacturing; Pepgen Duchenne trial put on hold

    Novo Nordisk is investing more than $1 billion in a new production facility in Denmark. Elsewhere, drugs from Neurocrine Biosciences, Checkpoint and Galderma won new FDA approvals.

    By BioPharma Dive staff • Dec. 16, 2024
  • A stylized illustration of a pill breaking apart into smaller pills. Explore the Trendline➔
    Image attribution tooltip
    Brian Tucker / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Trendline

    Top 5 stories from BioPharma Dive

    Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

    By BioPharma Dive staff
  • A sign spelling Merck hangs on the side of an office building
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck calls quits on two immunotherapies for cancer

    The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 testing.

    By • Dec. 16, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Padlock investors sue Bristol Myers; Dietmar Berger is Gilead’s new CMO

    Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal. Elsewhere, Gilead CEO Daniel O’Day hired Berger away from Sanofi. 

    By BioPharma Dive staff • Dec. 13, 2024
  • Scientific illustration of a migrating breast cancer cell
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    With new data, Lilly sets pace for next wave of breast cancer drugs

    While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace fulvestrant.

    By • Updated Dec. 11, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BenevolentAI restructures; Lilly preps $15B buyback program

    The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.

    By BioPharma Dive staff • Updated Dec. 17, 2024
  • Coins in glass and stack coins with tree.
    Image attribution tooltip

    kirisa99/istockphoto.com

    Image attribution tooltip
    Sponsored by Evaluate

    What’s behind pharma’s growth boost?

    Pharma is forecast for a 7.7% growth rate to 2030. What’s driving it? (hint: it’s not just obesity).

    Dec. 9, 2024
  • 3 people wearing lab coats and hairnets
    Image attribution tooltip
    Permission granted by Almac Clinical Services
    Image attribution tooltip
    Sponsored by Almac Clinical Services

    Clinical services organizations are critical to the future of pharma in the APAC market

    As APAC contract manufacturing grows, pharma companies turn to outsourcing for cost-effective solutions. 

    Dec. 9, 2024
  • A sign with Eli Lilly's logo sits outside of the company's headquarters on March 17, 2024 in Indianapolis.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly adds to obesity drug production push with $3B investment

    The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana and will help make more injectable drugs like fast-selling Zepbound.

    By • Dec. 6, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B

    The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut spending and the U.S. PTO withdrew a controversial proposed patent rule.

    By BioPharma Dive staff • Dec. 6, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novavax sells Czech plant to Novo; Relay licenses out a cancer drug

    Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy.

    By BioPharma Dive staff • Dec. 4, 2024
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial

    Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.

    By • Updated Dec. 4, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date

    Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a key PDUFA date and Fate Therapeutics swapped CEOs.

    By BioPharma Dive staff • Dec. 2, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Kronos, Idorsia plan layoffs; PTC shelves ALS drug

    Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC disclosed negative Phase 2 results for its ALS drug candidate utreloxastat.

    By BioPharma Dive staff • Nov. 27, 2024
  • A sign spelling Amgen hangs on the side of an office building
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark

    Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.

    By • Nov. 26, 2024
  • Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche’s TIGIT-targeting drug for cancer fails its biggest test

    Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in a closely followed Phase 3 study called SKYSCRAPER-01.

    By Ned Pagliarulo • Nov. 26, 2024
  • Merck sign
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    New data could help Merck expand use of cardiovascular drug

    Positive study results for Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming patent expirations this decade.

    By • Nov. 25, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial

    Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target in sight and an FDA veteran plans retirement.

    By BioPharma Dive staff • Nov. 22, 2024
  • An Amgen logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Amgen picks prolific biotech founder Chang as new top scientist

    Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to overcome the looming loss of exclusivity for some of its top-selling medicines.

    By Kristin Jensen • Nov. 21, 2024
  • People pass an office building with signage spelling Pfizer in New York City.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pfizer, under pressure to change, names oncology head as new R&D chief

    Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

    By Kristin Jensen • Nov. 20, 2024
  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.
    Image attribution tooltip

    Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says

    Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous form of its cancer drug.

    By • Nov. 19, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer

    The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless founded a new startup and Novartis licensed another radiopharma drug.

    By BioPharma Dive staff • Nov. 19, 2024
  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J pill clears skin in two late-stage psoriasis studies

    The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down the inflammation involved in psoriasis and other immune diseases.

    By Ned Pagliarulo • Nov. 19, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Halozyme bids for Evotec; BeiGene gets a new name

    The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first Lyfgenia revenue and Leerink built up its M&A team.

    By BioPharma Dive staff • Nov. 15, 2024
  • Merck sign
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy

    The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that recently bested Keytruda in a clinical trial. 

    By • Nov. 14, 2024